21st Austria weekly - Marinomed Vienna Insurance Group 21/11/2023 [pic1]Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters 2023 Q1-Q3 2022: 7.1 million due to continued demand for Carragelose virus blockers. The increase personnel costs higher R&D expenses and lower research subsidies were reflected operating result -4.4 -3.8 million. period amounted -5.6 million compared -5.8 prior-year period. For platform took necessary steps create an all-year product portfolio a expansion therapeutic area immunology with allergy blocker eye drops. market launches are already preparation 2024. Procter & Gamble also secured rights Carragelose-based spray USA. has paved way further important partnerships candidates Budesolv Tacrosolv which based on Marinosolv